[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100606375":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":41,"collaborators":19,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":19,"eligibilityCriteria":48,"healthyVolunteers":45,"sex":49,"minAge":50,"maxAge":19,"enrollmentInfo":51,"targetDuration":19,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":29,"whyStopped":19,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Singapore Eye Research Institute","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Quantum Molecular Resonance (QMR) Treatment","EXPERIMENTAL","Participants in this arm will receive Quantum Molecular Resonance (QMR) treatment using the Rexon-Eye device for a total of eight sessions, administered once weekly, with each session lasting 30 minutes. The study consists of nine visits in total: one pre-assessment visit, followed by the eight QMR treatment sessions. The efficacy of QMR treatment will be evaluated through various aspects, including in participants' self-reported symptom relief, clinical ocular surface assessments, and IVCM evidence of corneal nerve regeneration.",[13],"Device: Quantum Molecular Resonance (QMR) Treatment",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DEVICE","Quantum Molecular Resonance (QMR) treatment will be administered using the Rexon-Eye® device (Resono Ophthalmic, Sandrigo, Italy) according to the protocol recommended by the manufacturer. The device features a contact electrode embedded in a mask worn over the participant's closed eyes, and it delivers stimulation to the epidermis of the closed eyelids, extending up to the lid border with an intensity setting of 4-5 on a scale of 0-10. The treatment is non-invasive and painless.",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Yu-Chi Liu, MD, MCI, PhD","CONTACT","65 65767287","liu.yu.chi@snec.com.sg",[27],{"facility":28,"status":29,"city":30,"state":19,"zip":31,"country":30,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Singapore National Eye Centre","RECRUITING","Singapore","S169856","SG",{"type":34,"coordinates":35},"Point",[36,37],103.85007,1.28967,{"lat":37,"lon":36},[40],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},{"type":42,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100606375","efficacy-of-quantum-molecular-resonance-in-neuropathic-corneal-pain-and-corneal-nerve-regeneration-100606375",false,"NCT07174739","Efficacy of Quantum Molecular Resonance in Neuropathic Corneal Pain and Corneal Nerve Regeneration","Inclusion Criteria:\n\n* Be at least 21 years of age.\n* Regardless of gender (Male\u002FFemale).\n* Regardless of race (Chinese\u002FMalay\u002FIndian\u002FEurasian\u002FOthers).\n* Diagnosed with neuropathic corneal pain based on the following criteria: presence of neuropathic ocular symptoms (burning, stinging, photophobia, pain, severe dryness), absent or minimal slit-lamp findings to explain the symptoms and corneal nerve abnormalities as detected by IVCM (decreased corneal length and density, presence of neuromas).\n* Willing to receive all eye examinations in this study.\n\nExclusion Criteria:\n\n* Pregnant women.\n* Participants carrying active implantable devices (e.g., pacemakers and hearing aids).\n* Oncologic patients under treatment; patient who underwent ocular surgery in the last month.\n* Participants who had ocular infection within 6 months, or active ocular infection or inflammation; any concomitant ocular diseases that could potentially induce ocular pain, such as uveitis.","ALL","21 Years",{"count":52,"type":53},30,"ESTIMATED","INTERVENTIONAL",[56],"NA","The goal of this study is to evaluate whether Quantum Molecular Resonance (QMR) treatment can effectively reduce eye pain and stimulate corneal nerve regeneration in patients with neuropathic corneal pain (NCP). Participants diagnosed with NCP will attend a total of nine study visits, consisting of one baseline assessment and eight QMR treatment sessions. At each visit, participants will undergo a series of clinical examinations to evaluate changes in the ocular surface, corneal nerves, and tear proteins, and will complete questionnaires regarding their symptoms, eye pain, and quality of life. The investigators will compare these outcomes before and after QMR treatment to determine whether QMR treatment alleviates NCP symptoms and enhances ocular surface and corneal nerve health. The investigators hypothesize that QMR treatment will provide notable pain relief, promote corneal nerve regeneration, and improve overall quality of life for NCP patients.",[59],"Neuropathic Corneal Pain",[61,62,63,64,65],"neuropathic corneal pain","eye pain","QMR","Quantum Molecular Resonance","Rexon-Eye","2025-09-15",{"date":68,"type":69},"2025-09-19","ACTUAL",{"date":71,"type":69},"2023-11-01",{"date":73,"type":53},"2026-12-31",{"name":5,"class":6},1]